Table 2.
Crizotinib Treated Group 1 (CTG1) | Crizotinib Treated Group 2 (CTG2) | Non-Crizotinib Treated Group (NCTG) | |
---|---|---|---|
|
|||
No. patients | 32 | 19 | 19 |
| |||
Age (Median) | 54 yrs | 60 yrs | 63 yrs |
Range | 33 – 69 | 35 – 81 | 43 – 78 |
| |||
Cancer | |||
Non-small cell lung cancer | 31(97%) | 19 (100%) | 19 (100%) |
Colorectal cancer | 1 (3%) | 0 (0%) | 1 (5%) |
| |||
Molecular Status | |||
ALK rearranged | 26 (82%) | 17 (90%) | 2 (11%) |
ROS1 fusion gene | 2 (6%) | 1 (5%) | 0 (0%) |
MET amplification | 1 (3%) | 1 (5%) | 0 (0%) |
EGFR mutation | 1 (3%) | 0 (0%) | 5 (26%) |
KRAS mutation | 1 (3%) | 0 (0%) | 3 (16%) |
Undefined/Other | 1 (3%) | 0 (0%) | 9 (47%) |
| |||
Current Therapy | |||
Crizotinib | 32 (100%) | 19 (100%) | 0 (0%) |
Median duration | 6.3 months | 7.3 months | - |